Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 16, 2021

View Archived Issues

Polymer-mediated "immunocloaking" - A new paradigm for combating transplant rejection?

Phase I trial begins for DVX-201 allogeneic NK cells in COVID-19 patients

Trial starts enrollment to assess LY-3361237 in patients with psoriasis

TYK2 inhibitor NDI-034858 enters phase II investigation for plaque psoriasis

MedImmune patents new ADCs for cancer

Kangpu Biopharmaceuticals divulges CRBN-binding isoindolines

Beijing Jacobio Pharmaceuticals presents new AURK1 inhibitors

Apeximmune Therapeutics describes anti-B7-H4 constructs for cancer

Primary endpoint not met in phase II trial of trimodulin in patients with severe COVID-19

Lomecel-B improves physical function in phase IIb study in patients with aging frailty

Phase I study of tyrosine kinase 2 inhibitor ICP-332 begins in China

Phase Ib data reported for ITPP in patients with hepatopancreatobiliary tumors

SPTBN1 genetic variants found to be associated with neurodevelopmental syndrome

Leptin linked to severity of COVID-19

Enanta's HBV treatment begins phase I study

LAVA Therapeutics cleared to initiate clinical trial of LAVA-1207

FDA lifts clinical hold on trial of Danon disease treatment RP-A501

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...